← Leaderboards
James Alvan Longstreth
Us Worldmeds, Llc
$2,540,867
Attributed
$5,081,734
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–14$2M$1.5M$1M$500K$0
'11
'12
'13
'14
Funding mix
By agency
NIH$5,081,734 · 1
By mechanism
U01$5,081,734 · 1
Top collaborators
- Charles W. Gorodetzky6 shared
Most similar at Us Worldmeds, Llc
Same institution · by research overlap
- Charles W. Gorodetzky$20,848,803
- Kristen Leann Gullo$6,476,657
Others in their field
Top investigators on “Heroin”
- Sharon L. Walsh · University Of Kentucky$94,858,536
- Jeffrey H Samet · Boston University Medical Campus$88,830,747
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$44,251,981
- Marco Pravetoni · Hennepin Healthcare Research Institute$34,346,974
- Sandra D. Comer · New York State Psychiatric Institute$29,190,072
- Steffanie A Strathdee · University Of California, San Diego$18,906,458
Research focus
HeroinIntravenousAcuteFoodHepaticImpairmentAdrenergic AgonistsBuprenorphineAreaDoseHealthy VolunteerDrug KineticsBiological AvailabilityHydrochloride SaltEnd Stage Renal FailureBody Mass IndexEquilibriumEvaluationClinical PharmacologyFastingFatty Acid Glycerol EstersFda ApprovedAnalgesicsIntravenous Administration
Grant awards (6)
NDA-Enabling Phase I Lofexidine Program$1,438,532
U01 · FY2014 · DA · contact PI
NDA-Enabling Phase I Lofexidine Program$1,107,186
U01 · FY2013 · DA · contact PI
NDA-Enabling Phase I Lofexidine Program$91,375
U01 · FY2013 · DA · contact PI
NDA-Enabling Phase I Lofexidine Program$976,880
U01 · FY2012 · DA · contact PI
NDA-Enabling Phase I Lofexidine Program$468,517
U01 · FY2012 · DA · contact PI
NDA-Enabling Phase I Lofexidine Program$999,244
U01 · FY2011 · DA · contact PI